| Emerging pharmaceutical therapies for osteoarthritis A Latourte, M Kloppenburg, P Richette Nature Reviews Rheumatology 16 (12), 673-688, 2020 | 332 | 2020 |
| Systemic inhibition of IL-6/Stat3 signalling protects against experimental osteoarthritis A Latourte, C Cherifi, J Maillet, HK Ea, W Bouaziz, T Funck-Brentano, ... Annals of the rheumatic diseases 76 (4), 748-755, 2017 | 311 | 2017 |
| COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study J Avouac, E Drumez, E Hachulla, R Seror, S Georgin-Lavialle, ... The Lancet Rheumatology 3 (6), e419-e426, 2021 | 271 | 2021 |
| Uric acid and incident dementia over 12 years of follow-up: a population-based cohort study A Latourte, A Soumaré, T Bardin, F Perez-Ruiz, S Debette, P Richette Annals of the rheumatic diseases 77 (3), 328-335, 2018 | 135 | 2018 |
| Severity of COVID-19 and survival in patients with rheumatic and inflammatory diseases: data from the French RMD COVID-19 cohort of 694 patients FAI2R/SFR/SNFMI/SOFREMIP/CRI/IMIDIATE consortium and contributors Annals of the Rheumatic Diseases 80 (4), 527-538, 2021 | 99 | 2021 |
| 2020 recommendations from the French Society of Rheumatology for the management of gout: urate-lowering therapy T Pascart, A Latourte, RM Flipo, G Chalès, L Coblentz-Baumann, ... Joint Bone Spine 87 (5), 395-404, 2020 | 98 | 2020 |
| Efficacy of tocilizumab in patients with hand osteoarthritis: double blind, randomised, placebo-controlled, multicentre trial P Richette, A Latourte, J Sellam, D Wendling, M Piperno, P Goupille, ... Annals of the rheumatic diseases 80 (3), 349-355, 2021 | 93 | 2021 |
| Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend? P Richette, A Latourte, A Frazier Expert opinion on drug safety 14 (8), 1259-1268, 2015 | 78 | 2015 |
| The 2023 ACR/EULAR classification criteria for calcium pyrophosphate deposition disease A Abhishek, SK Tedeschi, T Pascart, A Latourte, N Dalbeth, T Neogi, ... Arthritis & Rheumatology 75 (10), 1703-1713, 2023 | 76 | 2023 |
| Prophylaxis for acute gout flares after initiation of urate-lowering therapy A Latourte, T Bardin, P Richette Rheumatology 53 (11), 1920-1926, 2014 | 76 | 2014 |
| Recommendations of the French Society of Rheumatology on pharmacological treatment of knee osteoarthritis J Sellam, A Courties, F Eymard, S Ferrero, A Latourte, P Ornetti, ... Joint Bone Spine 87 (6), 548-555, 2020 | 72 | 2020 |
| Uric acid and cognitive decline: a double-edge sword? A Latourte, T Bardin, P Richette Current opinion in rheumatology 30 (2), 183-187, 2018 | 54 | 2018 |
| Imaging findings suggestive of axial spondyloarthritis in diffuse idiopathic skeletal hyperostosis A Latourte, S Charlon, A Etcheto, A Feydy, Y Allanore, M Dougados, ... Arthritis Care & Research 70 (1), 145-152, 2018 | 47 | 2018 |
| Cardiac and renal protective effects of urate-lowering therapy P Richette, A Latourte, T Bardin Rheumatology 57 (suppl_1), i47-i50, 2018 | 46 | 2018 |
| Hyperuricemia, gout, and the brain—an update A Latourte, J Dumurgier, C Paquet, P Richette Current Rheumatology Reports 23 (12), 82, 2021 | 38 | 2021 |
| Identifying potential classification criteria for calcium pyrophosphate deposition disease: item generation and item reduction SK Tedeschi, T Pascart, A Latourte, C Godsave, B Kundakci, RP Naden, ... Arthritis care & research 74 (10), 1649-1658, 2022 | 36 | 2022 |
| Evaluation of lupus anticoagulant, damage, and remission as predictors of pregnancy complications in systemic lupus erythematosus: the French GR2 study M Larosa, V Le Guern, G Guettrot-Imbert, N Morel, N Abisror, ... Rheumatology 61 (9), 3657-3666, 2022 | 32 | 2022 |
| 2020 Recommendations from the French Society of Rheumatology for the management of gout: Management of acute flares A Latourte, T Pascart, RM Flipo, G Chalès, L Coblentz-Baumann, ... Joint Bone Spine 87 (5), 387-393, 2020 | 30 | 2020 |
| Do glucocorticoid injections increase the risk of knee osteoarthritis progression over 5 years? A Latourte, AC Rat, A Omorou, W Ngueyon‐Sime, F Eymard, J Sellam, ... Arthritis & rheumatology 74 (8), 1343-1351, 2022 | 29* | 2022 |
| Tocilizumab in symptomatic calcium pyrophosphate deposition disease: a pilot study A Latourte, HK Ea, A Frazier, A Blanchard, F Lioté, H Marotte, T Bardin, ... Annals of the Rheumatic Diseases 79 (8), 1126-1128, 2020 | 27 | 2020 |
